Cargando…

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer

Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating molecular profiling data with data from multiple genetic perturbation screens,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brough, Rachel, Gulati, Aditi, Haider, Syed, Kumar, Rahul, Campbell, James, Knudsen, Erik, Pettitt, Stephen J., Ryan, Colm J., Lord, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202330/ https://www.ncbi.nlm.nih.gov/pubmed/29915391 http://dx.doi.org/10.1038/s41388-018-0368-z

Ejemplares similares

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

Overcoming selection bias in synthetic lethality prediction
por: Seale, Colm, et al.
Publicado: (2022)

Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics
por: Lyu, Junfang, et al.
Publicado: (2020)

Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
por: Nowsheen, Somaira, et al.
Publicado: (2012)

Hyperactivated Wnt Signaling Induces Synthetic Lethal Interaction with Rb Inactivation by Elevating TORC1 Activities
por: Zhang, Tianyi, et al.
Publicado: (2014)

Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer
por: Kim, Nayoung, et al.
Publicado: (2015)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
por: Bartelink, Imke H., et al.
Publicado: (2017)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
por: Wu, Qin, et al.
Publicado: (2020)

Differential role of RB in response to UV and IR damage
por: Bosco, Emily E., et al.
Publicado: (2005)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality
por: Bray, Chandler, et al.
Publicado: (2023)

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells
por: Turchick, Audrey, et al.
Publicado: (2019)

Dual Inhibition of CDK4/Rb and PI3K/AKT/mTOR Pathways by ON123300 Induces Synthetic Lethality in Mantle Cell Lymphomas
por: Divakar, Saikrishna A., et al.
Publicado: (2015)

Synthetic Lethal Targeting of Mitotic Checkpoints in HPV-Negative Head and Neck Cancer
por: Deneka, Alexander Y., et al.
Publicado: (2020)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
por: Huang, Yajing, et al.
Publicado: (2020)

HSulf-1 and palbociclib exert synergistic antitumor effects on RB-positive triple-negative breast cancer
por: Chen, Fengxia, et al.
Publicado: (2020)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Complete Genome Sequences of T4-Like Bacteriophages RB3, RB5, RB6, RB7, RB9, RB10, RB27, RB33, RB55, RB59, and RB68
por: Yaung, Stephanie J., et al.
Publicado: (2015)

RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs
por: Robinson, Tyler J. W., et al.
Publicado: (2013)

RB deletion disrupts coordination between DNA replication licensing and mitotic entry in vivo
por: Bourgo, Ryan J., et al.
Publicado: (2011)

Synthetic lethality: emerging targets and opportunities in melanoma
por: Thompson, Nicola, et al.
Publicado: (2017)

The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control
por: Knudsen, Erik S., et al.
Publicado: (2018)

Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy
por: Song, Won-Min, et al.
Publicado: (2023)

Pan-cancer molecular analysis of the RB tumor suppressor pathway
por: Knudsen, Erik S., et al.
Publicado: (2020)

A Cell‐Penetrant Peptide Disrupting the Transcription Factor CP2c Complexes Induces Cancer‐Specific Synthetic Lethality
por: Son, Seung Han, et al.
Publicado: (2023)

Rapid Inhibitor Discovery by Exploiting Synthetic Lethality
por: Muscato, Jacob D., et al.
Publicado: (2022)

Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
por: Ebeid, Kareem, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q1sv5gh080grk74q1a29e9lkuh